Comparison of the Efficacy of Empagliflozin, Dapagliflozin, and Allopurinol Based on Serum Uric Acid Levels and Kidney Function in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study
Medical Sciences · 2025
DOI: 10.3390/medsci14010012 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Medical Sciences, 2025. Verfasst von Roland Fejes und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Surgical Research, Albert Szent-Györgyi Medical School, University of Szeged, Szőkefalvi-Nagy Béla Street 6, 6720 Szeged, Hungary. Hauptthemen laut MEDLINE: Glucosides, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Allopurinol. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Szeged.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Type 2 diabetes mellitus (T2DM) is often associated with hyperuricemia, both conditions worsening kidney function. Sodium–glucose cotransporter 2 (SGLT2) inhibitors improve glycemic control and kidney function; however, data on their long-term antihyperuricemic effects in real-world clinical settings remain limited. Therefore, we aimed to compare the effects of SGLT2 inhibitors versus allopurinol on serum uric acid (sUA), kidney function, and clinical outcomes.
Methods
This retrospective cohort study evaluated patients with T2DM and hyperuricemia initiated on 10 mg empagliflozin (n = 70), 10 mg dapagliflozin (n = 78), or 100 mg allopurinol (n = 66) between 1 January 2017, and 1 January 2020. Drug dosages were kept constant throughout the study. Baseline and follow-up data (3, 6, 12, 24, and 36 months) were collected.
Results
Over 36 months, empagliflozin and dapagliflozin significantly reduced sUA (from 452 (95) to 399 (69) µmol/L and from 450 (81) to 364 (71) µmol/L, respectively) and stabilized eGFR without a significant decline. Allopurinol also reduced sUA (from 430 (89) to 345 (69) µmol/L) but was associated with a progressive eGFR decline (from 70 (35) to 57 (32) mL/min/1.73 m2). Mortality was the highest in the allopurinol group; however, therapy discontinuation was the lowest with this treatment.
Conclusions
SGLT2 inhibitors achieved comparable sUA reduction to allopurinol by 36 months while preserving eGFR. Allopurinol was associated with higher mortality and hospitalization rates; SGLT2 inhibitor therapy was associated with favorable multidomain outcomes, but strategies to address adverse effects are needed to enhance adherence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Surgical Research, Albert Szent-Györgyi Medical School, University of Szeged, Szőkefalvi-Nagy Béla Street 6, 6720 Szeged, Hungary.
- Department of Internal Medicine, Hódmezővásárhely-Makó Healthcare Center, 6900 Makó, Hungary.
- Department of Medical Physics and Informatics, Albert Szent-Györgyi Medical School, University of Szeged, 6725 Szeged, Hungary.
ORCID-Profile: Roland Fejes, Tamás Lantos
Förderung
- University of Szeged
Zitieren
APA
Fejes, R., Jámbor, T., Lantos, T., & Tallósy, S. P. (2025). Comparison of the Efficacy of Empagliflozin, Dapagliflozin, and Allopurinol Based on Serum Uric Acid Levels and Kidney Function in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study. Medical Sciences. https://doi.org/10.3390/medsci14010012
Vancouver
Fejes R, Jámbor T, Lantos T, Tallósy SP. Comparison of the Efficacy of Empagliflozin, Dapagliflozin, and Allopurinol Based on Serum Uric Acid Levels and Kidney Function in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study. Medical Sciences. 2025. doi:10.3390/medsci14010012
BibTeX
@article{Fejes2025,
author = {Fejes, Roland and Jámbor, Tamás and Lantos, Tamás and Tallósy, Szabolcs Péter},
title = {Comparison of the Efficacy of Empagliflozin, Dapagliflozin, and Allopurinol Based on Serum Uric Acid Levels and Kidney Function in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study},
journal = {Medical Sciences},
year = {2025},
doi = {10.3390/medsci14010012}
}
EUVIMED